While the IMbrave152/SKYSCRAPER-14 trial showed no added benefit with tiragolumab, other studies are ongoing to explore the potential of additional immune checkpoint inhibition in combination with standard therapy
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
For Prof. Brigette Ma, dealing with diversity and finding opportunities in criticisms are essential to grow as oncology professionals
Extensive research is focusing on the development of tools that may enhance drug development and personalised oncology in the near future
As a proof of concept, an AI-powered large language model matching platform shows promise in patient selection
While synthetic real-world data may help overcome current challenges in clinical trials, it also introduces new complexities
The combination of lenvatinib plus everolimus improved progression-free survival in the LenCabo trial, but toxicity must be carefully assessed
In the evERA BC trial, giredestrant plus everolimus led to a prolonged progression-free survival
In early phase studies, IAG933 and VT3989 led to encouraging disease control rates with manageable toxicity
The promises of a tumour-agnostic oncology are still challenged by conventional clinical trial design and regulatory processes
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.